Michael A Metzger Syndax Pharmaceuticals Inc (SNDX) insider trading activity

Michael A Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc. Currently has a direct ownership of 306,195 shares of SNDX, which is worth approximately $4.2 Million. The most recent transaction as insider was on Dec 17, 2021, when has been sold 1,676 shares (Common Stock) at a price of $6.38 per share, resulting in proceeds of $10,693. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 306K

86.81% 3M change

86.81% 12M change

Total Value Held $4.2 Million

Michael A Metzger Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2021	BUY Exercise of conversion of derivative security	$10,693 $6.38 p/Share	1,676 Added 7.98%	19,335 Common Stock
Dec 16 2021	SELL Open market or private sale	$433,402 $19.08 p/Share	22,715 Reduced 56.26%	17,659 Common Stock
Dec 16 2021	BUY Exercise of conversion of derivative security	$144,922 $6.38 p/Share	22,715 Added 36.0%	40,374 Common Stock
Dec 13 2021	SELL Open market or private sale	$697,401 $19.05 p/Share	36,609 Reduced 67.46%	17,659 Common Stock
Dec 13 2021	BUY Exercise of conversion of derivative security	$248,575 $6.79 p/Share	36,609 Added 41.21%	52,223 Common Stock
Oct 26 2021	SELL Open market or private sale	$312,883 $19.2 p/Share	16,296 Reduced 47.99%	17,659 Common Stock
Oct 26 2021	BUY Exercise of conversion of derivative security	$117,331 $7.2 p/Share	16,296 Added 32.43%	33,955 Common Stock
Oct 25 2021	SELL Open market or private sale	$855,187 $19.13 p/Share	44,704 Reduced 71.68%	17,659 Common Stock
Oct 25 2021	BUY Exercise of conversion of derivative security	$321,869 $7.2 p/Share	44,704 Added 41.75%	62,363 Common Stock
Sep 27 2021	SELL Open market or private sale	$476,766 $19.51 p/Share	24,437 Reduced 58.05%	17,659 Common Stock
Sep 27 2021	BUY Exercise of conversion of derivative security	$175,946 $7.2 p/Share	24,437 Added 36.73%	42,096 Common Stock
Sep 22 2021	SELL Open market or private sale	$5,706 $19.02 p/Share	300 Reduced 1.67%	17,659 Common Stock
Sep 22 2021	BUY Exercise of conversion of derivative security	$2,160 $7.2 p/Share	300 Added 1.64%	17,959 Common Stock
Sep 21 2021	SELL Open market or private sale	$92,121 $19.16 p/Share	4,808 Reduced 21.4%	17,659 Common Stock
Sep 21 2021	BUY Exercise of conversion of derivative security	$34,618 $7.2 p/Share	4,808 Added 17.63%	22,467 Common Stock
Sep 20 2021	SELL Open market or private sale	$605,194 $19.24 p/Share	31,455 Reduced 64.04%	17,659 Common Stock
Sep 20 2021	BUY Exercise of conversion of derivative security	$226,476 $7.2 p/Share	31,455 Added 39.04%	49,114 Common Stock
Sep 14 2021	SELL Open market or private sale	$849,283 $19.15 p/Share	44,349 Reduced 71.52%	17,659 Common Stock
Sep 14 2021	BUY Exercise of conversion of derivative security	$319,313 $7.2 p/Share	44,349 Added 41.7%	62,008 Common Stock
Sep 13 2021	SELL Open market or private sale	$316,702 $19.02 p/Share	16,651 Reduced 48.53%	17,659 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$119,887 $7.2 p/Share	16,651 Added 32.67%	34,310 Common Stock
Feb 01 2021	SELL Open market or private sale	$302,850 $20.19 p/Share	15,000 Reduced 45.93%	17,659 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$108,000 $7.2 p/Share	15,000 Added 31.47%	32,659 Common Stock
Dec 01 2020	SELL Open market or private sale	$344,550 $22.97 p/Share	15,000 Reduced 45.93%	17,659 Common Stock
Dec 01 2020	BUY Exercise of conversion of derivative security	$108,000 $7.2 p/Share	15,000 Added 31.47%	32,659 Common Stock

Also insider at

CTIC

CTI BIOPHARMA CORP Healthcare

Director

PYXS

Pyxis Oncology, Inc. Healthcare

MAM